{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:47:06Z","timestamp":1784814426960,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05384-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:53:15Z","timestamp":1751388795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA"],"prefix":"10.1038","volume":"15","author":[{"given":"Alessandra","family":"Virga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Urbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Polano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Petracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tedaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Marisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ambrosini-Spaltro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zampiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Cenacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ulivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"2","key":"5384_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10 (2), 63\u201389. https:\/\/doi.org\/10.14740\/wjon1191 (2019).","journal-title":"World J. Oncol."},{"issue":"3","key":"5384_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"5384_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72 (1), 7\u201333. https:\/\/doi.org\/10.3322\/caac.21708 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"5384_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11255-019-02339-3","volume":"52","author":"H Kodama","year":"2020","unstructured":"Kodama, H. et al. Castration-resistant prostate cancer without metastasis at presentation May achieve cancer-specific survival in patients who underwent prior radical prostatectomy. Int. Urol. Nephrol. 52 (4), 671\u2013679. https:\/\/doi.org\/10.1007\/s11255-019-02339-3 (2020).","journal-title":"Int. Urol. Nephrol."},{"issue":"1","key":"5384_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur. Urol. 76 (1), 89\u201397. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.045 (2019).","journal-title":"Eur. Urol."},{"issue":"7","key":"5384_CR6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41416-023-02354-3","volume":"129","author":"V Conteduca","year":"2023","unstructured":"Conteduca, V., Brighi, N., Schepisi, G. & De Giorgi, U. Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer. Br. J. Cancer. 129 (7), 1050\u20131060. https:\/\/doi.org\/10.1038\/s41416-023-02354-3 (2023).","journal-title":"Br. J. Cancer"},{"issue":"3","key":"5384_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2018.09.049","volume":"75","author":"V Conteduca","year":"2019","unstructured":"Conteduca, V. et al. Plasma androgen receptor and docetaxel for metastatic Castration-resistant prostate Cancer. Eur. Urol. 75 (3), 368\u2013373. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.049 (2019).","journal-title":"Eur. Urol."},{"issue":"25","key":"5384_CR8","doi-asserted-by":"publisher","first-page":"37839","DOI":"10.18632\/oncotarget.9341","volume":"7","author":"S Salvi","year":"2016","unstructured":"Salvi, S. et al. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget 7 (25), 37839\u201337845. https:\/\/doi.org\/10.18632\/oncotarget.9341 (2016).","journal-title":"Oncotarget"},{"issue":"1","key":"5384_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41391-017-0023-8","volume":"21","author":"J Gandhi","year":"2018","unstructured":"Gandhi, J. et al. The molecular biology of prostate cancer: Current Understanding and clinical implications. Prostate Cancer Prostatic Dis. 21 (1), 22\u201336. https:\/\/doi.org\/10.1038\/s41391-017-0023-8 (2018).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"5384_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00283","author":"JH Chung","year":"2019","unstructured":"Chung, J. H. et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol.  https:\/\/doi.org\/10.1200\/PO.18.00283 (2019).","journal-title":"JCO Precis Oncol."},{"issue":"22","key":"5384_CR11","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic Castration-Resistant prostate Cancer. N Engl. J. Med. 382 (22), 2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440 (2020).","journal-title":"N Engl. J. Med."},{"issue":"24","key":"5384_CR12","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain, M. et al. Survival with Olaparib in metastatic Castration-Resistant prostate Cancer. N Engl. J. Med. 383 (24), 2345\u20132357. https:\/\/doi.org\/10.1056\/NEJMoa2022485 (2020).","journal-title":"N Engl. J. Med."},{"issue":"8","key":"5384_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Rucaparib or physician\u2019s choice in metastatic prostate Cancer. N Engl. J. Med. 388 (8), 719\u2013732. https:\/\/doi.org\/10.1056\/NEJMoa2214676 (2023).","journal-title":"N Engl. J. Med."},{"issue":"9","key":"5384_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 34 (9), 772\u2013782. https:\/\/doi.org\/10.1016\/j.annonc.2023.06.009 (2023).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"5384_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24 (10), 1094\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(23)00382-0 (2023).","journal-title":"Lancet Oncol."},{"issue":"1","key":"5384_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi, K. et al. First-line Talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat. Med. 30 (1), 257\u2013264. https:\/\/doi.org\/10.1038\/s41591-023-02704-x (2024).","journal-title":"Nat. Med."},{"issue":"7406","key":"5384_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (7406), 239\u2013243. https:\/\/doi.org\/10.1038\/nature11125 (2012).","journal-title":"Nature"},{"issue":"5","key":"5384_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-Repair gene mutations in men with metastatic prostate Cancer. N Engl. J. Med. 375 (5), 443\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1603144 (2016).","journal-title":"N Engl. J. Med."},{"key":"5384_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euros.2024.01.015","volume":"61","author":"C Casadei","year":"2024","unstructured":"Casadei, C. et al. Inherited mutations in DNA damage repair genes in Italian men with metastatic prostate cancer: results from the Meet-URO 10 study. Eur. Urol. Open. Sci. 61, 44\u201351. https:\/\/doi.org\/10.1016\/j.euros.2024.01.015 (2024).","journal-title":"Eur. Urol. Open. Sci."},{"issue":"9","key":"5384_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker, C. et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 31 (9), 1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011 (2020).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"5384_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","volume":"7","author":"M Schostak","year":"2024","unstructured":"Schostak, M. et al. Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate Cancer. Eur. Urol. Oncol. 7 (3), 344\u2013354. https:\/\/doi.org\/10.1016\/j.euo.2023.08.004 (2024).","journal-title":"Eur. Urol. Oncol."},{"issue":"10","key":"5384_CR22","doi-asserted-by":"publisher","first-page":"e2021692","DOI":"10.1001\/jamanetworkopen.2020.21692","volume":"3","author":"S Schmid","year":"2020","unstructured":"Schmid, S. et al. Activity of Platinum-Based chemotherapy in patients with advanced prostate Cancer with and without DNA repair gene aberrations. JAMA Netw. Open. 3 (10), e2021692. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.21692 (2020).","journal-title":"JAMA Netw. Open."},{"issue":"4","key":"5384_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate Cancer. Eur. Urol. 76 (4), 469\u2013478. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030 (2019).","journal-title":"Eur. Urol."},{"issue":"9","key":"5384_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41416-021-01508-5","volume":"125","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi, U. et al. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a phase 2 trial. Br. J. Cancer. 125 (9), 1226\u20131232. https:\/\/doi.org\/10.1038\/s41416-021-01508-5 (2021).","journal-title":"Br. J. Cancer"},{"issue":"7_suppl","key":"5384_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2019.37.7_suppl.272","volume":"37","author":"V Conteduca","year":"2019","unstructured":"Conteduca, V. et al. Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy. J. Clin. Oncol. 37 (7_suppl), 272\u2013272. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.272 (2019).","journal-title":"J. Clin. Oncol."},{"key":"5384_CR26","doi-asserted-by":"publisher","first-page":"e2200085","DOI":"10.1200\/PO.22.00085","volume":"6","author":"S Takamatsu","year":"2022","unstructured":"Takamatsu, S. et al. Utility of homologous recombination deficiency biomarkers across Cancer types. JCO Precis Oncol. 6, e2200085. https:\/\/doi.org\/10.1200\/PO.22.00085 (2022).","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"5384_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.urolonc.2020.03.001","volume":"38","author":"C Nientiedt","year":"2020","unstructured":"Nientiedt, C. et al. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-na\u00efve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol. Oncol. 38 (7), 637. e17-637.e27 (2020).","journal-title":"Urol. Oncol."},{"key":"5384_CR28","doi-asserted-by":"publisher","unstructured":"Abida, W. et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.17.00029 (2017).","DOI":"10.1200\/PO.17.00029"},{"issue":"8","key":"5384_CR29","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain, M. et al. Tumor genomic testing for >4,000 men with metastatic Castration-resistant prostate Cancer in the phase III trial profound (Olaparib). Clin. Cancer Res. 28 (8), 1518\u20131530. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3940 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"5384_CR30","doi-asserted-by":"publisher","first-page":"813e","DOI":"10.1016\/j.urolonc.2019.06.015","volume":"37","author":"J Zhu","year":"2019","unstructured":"Zhu, J. et al. Clinical utility of foundationone tissue molecular profiling in men with metastatic prostate cancer. Urol. Oncol. 37 (11), 813e. 1-813.e9 (2019).","journal-title":"Urol. Oncol."},{"issue":"1","key":"5384_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","volume":"53","author":"DS Kim","year":"2021","unstructured":"Kim, D. S., Camacho, C. V. & Kraus, W. L. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp. Mol. Med. 53 (1), 42\u201351. https:\/\/doi.org\/10.1038\/s12276-021-00557-3 (2021).","journal-title":"Exp. Mol. Med."},{"key":"5384_CR32","doi-asserted-by":"publisher","first-page":"102860","DOI":"10.1016\/j.critrevonc.2019.102860","volume":"145","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Exosomal MicroRNAs as liquid biopsy biomarkers in prostate cancer. Crit. Rev. Oncol. Hematol. 145, 102860. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102860 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"5384_CR33","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP Inhibition. Cancer Discov. 7 (9), 1006\u20131017. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0261 (2017).","journal-title":"Cancer Discov"},{"issue":"2","key":"5384_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin, K. K. et al. BRCA reversion mutations in Circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor Rucaparib in High-Grade ovarian carcinoma. Cancer Discov. 9 (2), 210\u2013219. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0715 (2019).","journal-title":"Cancer Discov"},{"issue":"11","key":"5384_CR35","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1158\/1078-0432.CCR-19-2933","volume":"26","author":"N Vidula","year":"2020","unstructured":"Vidula, N. et al. Routine Plasma-Based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors. Clin. Cancer Res. 26 (11), 2546\u20132555. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2933 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"7809","key":"5384_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581 (7809), 434\u2013443. https:\/\/doi.org\/10.1038\/s41586-020-2308-7 (2020).","journal-title":"Nature"},{"issue":"5","key":"5384_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet. Med. 17 (5), 405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30 (2015).","journal-title":"Genet. Med."},{"issue":"1","key":"5384_CR38","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8 (1), 1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y (2017).","journal-title":"Nat. Commun."},{"issue":"13","key":"5384_CR39","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","volume":"26","author":"KH Stopsack","year":"2020","unstructured":"Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic Castration-Sensitive prostate Cancer. Clin. Cancer Res. 26 (13), 3230\u20133238. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0168 (2020).","journal-title":"Clin. Cancer Res."},{"key":"5384_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010165","author":"T Borbiev","year":"2023","unstructured":"Borbiev, T., Kohaar, I. & Petrovics, G. Clinical biofluid assays for prostate Cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16010165 (2023).","journal-title":"Cancers (Basel)"},{"key":"5384_CR41","doi-asserted-by":"publisher","first-page":"4358292","DOI":"10.1155\/2016\/4358292","volume":"2016","author":"F Martignano","year":"2016","unstructured":"Martignano, F. et al. GSTP1 methylation and protein expression in prostate cancer: diagnostic implications. Dis. Markers. 2016, 4358292. https:\/\/doi.org\/10.1155\/2016\/4358292 (2016).","journal-title":"Dis. Markers"},{"issue":"12","key":"5384_CR42","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00259-018-4067-3","volume":"45","author":"P Caroli","year":"2018","unstructured":"Caroli, P. et al. 68Ga-PSMA PET\/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur. J. Nucl. Med. Mol. Imaging. 45 (12), 2035\u20132044. https:\/\/doi.org\/10.1007\/s00259-018-4067-3 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"30","key":"5384_CR43","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.1200\/JCO.2005.05.525","volume":"23","author":"SJ Freedland","year":"2005","unstructured":"Freedland, S. J. et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J. Clin. Oncol. 23 (30), 7546\u20137554. https:\/\/doi.org\/10.1200\/JCO.2005.05.525 (2005).","journal-title":"J. Clin. Oncol."},{"key":"5384_CR44","unstructured":"FDA. NGS FoundationOne\u00aeLiquid CDx assays FDA approval."},{"issue":"1","key":"5384_CR45","doi-asserted-by":"publisher","first-page":"16774","DOI":"10.1038\/s41598-020-72818-6","volume":"10","author":"D Kleftogiannis","year":"2020","unstructured":"Kleftogiannis, D. et al. Detection of genomic alterations in breast cancer with Circulating tumour DNA sequencing. Sci. Rep. 10 (1), 16774. https:\/\/doi.org\/10.1038\/s41598-020-72818-6 (2020).","journal-title":"Sci. Rep."},{"issue":"7793","key":"5384_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","unstructured":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578 (7793), 82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6 (2020).","journal-title":"Nature"},{"key":"5384_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189783","author":"A Ghose","year":"2021","unstructured":"Ghose, A., Moschetta, M., Pappas-Gogos, G., Sheriff, M. & Boussios, S. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22189783 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"5384_CR48","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","volume":"27","author":"H Tukachinsky","year":"2021","unstructured":"Tukachinsky, H. et al. Genomic analysis of Circulating tumor DNA in 3,334 patients with advanced prostate Cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin. Cancer Res. 27 (11), 3094\u20133105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4805 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"5384_CR49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3892\/ijo.2019.4842","volume":"55","author":"SH Lang","year":"2019","unstructured":"Lang, S. H. et al. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int. J. Oncol. 55 (3), 597\u2013616. https:\/\/doi.org\/10.3892\/ijo.2019.4842 (2019).","journal-title":"Int. J. Oncol."},{"key":"5384_CR50","volume-title":"Prostate Cancer [Internet]","author":"M Teroerde","year":"2021","unstructured":"Teroerde, M. et al. Revisiting the role of p53 in prostate Cancer. In: (eds Bott, S. R. J. & Ng, K. L.) Prostate Cancer [Internet]. Brisbane (AU): Exon; (2021). May 27. Chapter 8."},{"issue":"1","key":"5384_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/2159-8290.CD-23-0456","volume":"14","author":"D Wong","year":"2024","unstructured":"Wong, D. et al. Early Cancer detection in Li-Fraumeni syndrome with Cell-Free DNA. Cancer Discov. 14 (1), 104\u2013119. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0456 (2024).","journal-title":"Cancer Discov"},{"issue":"3","key":"5384_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-021-01635-z","volume":"126","author":"Y Liu","year":"2022","unstructured":"Liu, Y. At the dawn: cell-free DNA fragmentomics and gene regulation. Br. J. Cancer. 126 (3), 379\u2013390. https:\/\/doi.org\/10.1038\/s41416-021-01635-z (2022).","journal-title":"Br. J. Cancer"},{"key":"5384_CR53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cancergen.2021.05.014","volume":"256\u2013257","author":"ES Kuligina","year":"2021","unstructured":"Kuligina, E. S. et al. Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal. Cancer Genet. 256\u2013257, 165\u2013178. https:\/\/doi.org\/10.1016\/j.cancergen.2021.05.014 (2021).","journal-title":"Cancer Genet."},{"key":"5384_CR54","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.jshs.2025.101036","volume":"17","author":"JC Brown","year":"2025","unstructured":"Brown, J. C. et al. Effects of exercise on inflammation, Circulating tumor cells, and Circulating tumor DNA in colorectal cancer. J. Sport Health Sci. 17:101036. https:\/\/doi.org\/10.1016\/j.jshs.2025.101036 (2025).","journal-title":"J. Sport Health Sci. 2025 Mar."},{"key":"5384_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123170","author":"TR McFarland","year":"2022","unstructured":"McFarland, T. R. et al. Detection of BRCA1, and BRCA2 alterations in matched tumor tissue and circulating cell-free DNA in patients with prostate Cancer in a real-world setting. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10123170 (2022).","journal-title":"Biomedicines"},{"issue":"4","key":"5384_CR56","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","volume":"28","author":"JK Lee","year":"2022","unstructured":"Lee, J. K. et al. The Pan-Tumor landscape of targetable kinase fusions in Circulating tumor DNA. Clin. Cancer Res. 28 (4), 728\u2013737. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2136 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"5384_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","volume":"7","author":"K Jensen","year":"2021","unstructured":"Jensen, K. et al. Association of clonal hematopoiesis in DNA repair genes with prostate Cancer plasma Cell-free DNA testing interference. JAMA Oncol. 7 (1), 107. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5161 (2021).","journal-title":"JAMA Oncol."},{"key":"5384_CR58","doi-asserted-by":"publisher","first-page":"e2200583","DOI":"10.1200\/PO.22.00583","volume":"7","author":"M Aldea","year":"2023","unstructured":"Aldea, M. et al. Liquid biopsies for circulating tumor DNA detection May reveal occult hematologic malignancies in patients with solid tumors. JCO Precis Oncol. 7, e2200583. https:\/\/doi.org\/10.1200\/PO.22.00583 (2023).","journal-title":"JCO Precis Oncol."},{"issue":"26","key":"5384_CR59","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl. J. Med. 371 (26), 2488\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa1408617 (2014).","journal-title":"N Engl. J. Med."},{"issue":"22","key":"5384_CR60","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood-2018-03-840629","volume":"131","author":"EA Severson","year":"2018","unstructured":"Severson, E. A. et al. Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131 (22), 2501\u20132505. https:\/\/doi.org\/10.1182\/blood-2018-03-840629 (2018).","journal-title":"Blood"},{"issue":"1","key":"5384_CR61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","volume":"61","author":"E Heitzer","year":"2015","unstructured":"Heitzer, E., Ulz, P. & Geigl, J. B. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61 (1), 112\u2013123. https:\/\/doi.org\/10.1373\/clinchem.2014.222679 (2015).","journal-title":"Clin. Chem."},{"issue":"7","key":"5384_CR62","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-17-0061","volume":"16","author":"YK Chae","year":"2017","unstructured":"Chae, Y. K. et al. Concordance of genomic alterations by Next-Generation sequencing in tumor tissue versus Circulating tumor DNA in breast Cancer. Mol. Cancer Ther. 16 (7), 1412\u20131420. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0061 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"5384_CR63","doi-asserted-by":"publisher","first-page":"117955492211168","DOI":"10.1177\/11795549221116834","volume":"16","author":"Y He","year":"2022","unstructured":"He, Y. et al. Concordance of genomic profiles in matched tissue and plasma samples from Chinese patients with lung Cancer. Clin. Med. Insights Oncol. 16, 11795549221116834. https:\/\/doi.org\/10.1177\/11795549221116834 (2022).","journal-title":"Clin. Med. Insights Oncol."},{"key":"5384_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx118","author":"AW Wyatt","year":"2017","unstructured":"Wyatt, A. W. et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate Cancer. J. Natl. Cancer Inst.. https:\/\/doi.org\/10.1093\/jnci\/djx118 (2017).","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"5384_CR65","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13073-022-01080-4","volume":"14","author":"E Grist","year":"2022","unstructured":"Grist, E. et al. Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Med. 14 (1), 102. https:\/\/doi.org\/10.1186\/s13073-022-01080-4 (2022).","journal-title":"Genome Med."},{"key":"5384_CR66","doi-asserted-by":"crossref","unstructured":"Sophie, C. et al. A Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies. In:; 2023:3005. (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.3005"},{"key":"5384_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122109","author":"AD Choudhury","year":"2018","unstructured":"Choudhury, A. D. et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight.  https:\/\/doi.org\/10.1172\/jci.insight.122109 (2018).","journal-title":"JCI insight"},{"issue":"1","key":"5384_CR68","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca, N. M. et al. Prediction of plasma ctdna fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat. Commun. 15 (1), 1828. https:\/\/doi.org\/10.1038\/s41467-024-45475-w (2024).","journal-title":"Nat. Commun."},{"issue":"6","key":"5384_CR69","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","volume":"32","author":"A Jayaram","year":"2021","unstructured":"Jayaram, A. et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 32 (6), 726\u2013735. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.196 (2021).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"5384_CR70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ajur.2022.11.002","volume":"10","author":"W He","year":"2023","unstructured":"He, W., Xiao, Y., Yan, S., Zhu, Y. & Ren, S. Cell-free DNA in the management of prostate cancer: Current status and future prospective. Asian J. Urol. 10(3), 298\u2013316. https:\/\/doi.org\/10.1016\/j.ajur.2022.11.002 (2023).","journal-title":"Asian J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05384-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05384-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05384-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:53:17Z","timestamp":1751388797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05384-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5384"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05384-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods used in our studies involving human participants adhered strictly to the ethical guidelines of our institutional research committee, aligning with the principles outlined in the 1964 Helsinki declaration and its subsequent modifications, or equivalent ethical norms. This prospective study, with protocol code 0004169\/2017 approved on 15\/06\/2017, was authorized by the Institutional Review Board of IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola, Italy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"21296"}}